Doctors are increasingly using contrast-enhanced ultrasound (CEUS) for imaging kidney masses in patients with polycystic kidney disease, often bypassing CT scans altogether due to CEUS’s effectiveness. “They go right to CEUS and no longer bother with CT,” said Dr. Richard…
An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…
Daiichi Sankyo Europe (Daiichi Sankyo) has announced an enhanced commitment to tackling significant gaps in cardiovascular care, focusing on disparities in treatment and outcomes among different patient groups. This renewed focus follows the presentation of data from sub-analyses of the…
Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS® (mavacamten) in adults with New York Heart Association (NYHA) class…
Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris from September 19-22, 2024. The company will host a symposium…
EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®. Caris, a U.S.-based leader in next-generation AI TechBio and precision…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today the results of the Phase 3 PALISADE study evaluating investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a rare and severe genetic condition with no approved treatments in the U.S. The study…
Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) have announced the start of the 19th annual Blood Collectors Week, taking place from September 1 to September 7, 2024. This week celebrates the dedicated professionals who…
Elixir Medical, a developer of innovative cardiovascular technologies, announced that the INFINITY-SWEDEHEART Randomized Controlled Trial (RCT) has met its primary endpoint. The trial compared the novel DynamX® Coronary Bioadaptor System with the Resolute Onyx™ zotarolimus drug-eluting stent (DES), showing non-inferiority…
Daiichi Sankyo Europe today reaffirmed its dedication to tackling unmet needs and barriers in cardiovascular care by highlighting treatment disparities and outcomes among different patient groups. This announcement coincides with the presentation of new data from sub-analyses of the SANTORINI…
